Food and Drug Administration approved a new indication for use for Wegovy (Semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight
Adlyxin (lixisenatide, from Sanofi-Aventis), once daily injection, approved 2016

How BPC-157 Works BPC-157 promotes rapid recovery and cellular repair by: Stimulating angiogenesis (new blood vessel formation) Enhancing collagen synthesis for stronger connective tissue Reducing inflammation and oxidative stress Regenerating intestinal lining and restoring gut-brain axis balance Improving blood flow, nitric oxide function, and tissue oxygenation Conditions Supported by BPC-157 Therapy Muscle, Tendon & Ligament Repair Muscle tears, microtears, and overuse injuries Tendonitis (Achilles, patellar, rotator cuff, biceps) Ligament injuries (ACL, MCL, meniscus) Sports injuries and post-surgical recovery Joint & Bone Regeneration Osteoarthritis and degenerative joint pain Cartilage loss and stiffness Bone fractures and delayed healing Post-reconstruction ligament rehabilitation Nerve & Pain Syndromes Peripheral nerve damage Sciatica and neuropathic pain Fibromyalgia and myofascial pain BPC-157 and Gut-Brain Axis Health BPC-157 supports the gut-brain axis the communication link between digestion and mental health by repairing the gut lining and reducing inflammation

periodic monitoring is prudent
Led by senior scientist Benjamin Henderson, PhD, the team is utilizing cutting-edge technology to identify biomarkers that could potentially aid in the early diagnosis of Parkinsons disease